The results indicated that age, smoking, diabetes, BMI, tumor location, lung metastasis, ALB, and CEA were independent risk factors for myelosuppression in CRC patients undergoing first-line chemotherapy (Table 3). This evidence concerns the gene CEACAM5 and diabetes mellitus.